America Should Reward Better Medicines
· deals
The Price of Innovation: How Government Controls Could Stifle Breakthroughs in Medicine
The recent proposal from the Centers for Medicare & Medicaid Services (CMS) to broaden the criteria for grouping medicines together under price controls has sent shockwaves through the pharmaceutical industry. At first glance, this move might seem like a harmless tweak to an existing policy. However, it has far-reaching implications that could stifle innovation in medicine.
One of the most significant consequences of this proposal is its potential to discourage investment in new medicines. When investors and manufacturers know that a successful follow-on treatment will be immediately pulled into an older medicine’s price-control regime, they may conclude that the investment isn’t worth making. This has serious implications for patients who rely on breakthroughs in cancer treatments, for example. A breakthrough in delivering a particular medication through an intravenous infusion might seem like a minor improvement at first glance, but it can be a game-changer for patients who have to travel hours to receive treatment.
The real issue here is not just about the short-term cost savings but about the long-term consequences of stifling innovation. By discouraging investment in new medicines, policymakers are essentially saying that they value cheap medicine over better medicine. They are trading off potential cures and treatment options for a supposedly lower price today. This is economically foolish and potentially devastating for patients.
Moreover, this proposal raises serious questions about whether CMS is exceeding its authority. The FDA determines whether a medicine is sufficiently distinct, safe, and effective to receive separate approval. CMS shouldn’t be allowed to erase that distinction through regulatory sleight of hand simply to expand the reach of federal price controls.
Policymakers should focus on reducing costs by confronting opaque practices in the insurance industry and pharmacy-benefit managers, increasing competition, and forcing wealthy foreign countries to stop freeloading on U.S. innovation. President Trump has correctly identified these distortions and encouraged more than $500 billion in private-sector commitments to expand domestic pharmaceutical research, manufacturing, and employment.
The United States didn’t become the world’s medical-innovation leader through central planning; it did so because scientists, entrepreneurs, and investors were willing to take extraordinary risks in pursuit of extraordinary breakthroughs. We should reward them when they succeed—especially when an existing treatment is transformed into something that helps more patients.
The Trump Administration should reject CMS’ proposed expansion of this failed policy. America’s goal should be more cures, more treatment options, and better care, not fewer innovations dictated by Washington bureaucrats. By doing so, we can ensure that the medicines of tomorrow are developed with the same spirit of innovation and risk-taking that has always driven American medical progress.
Reader Views
- SBSam B. · deal hunter
This proposal is about more than just medicine - it's about how we value innovation in America. By tying prices of new medicines to older ones, CMS is essentially creating a disincentive for pharma companies to invest in R&D. But what about the existing medicines that are already in development? Do we really want to freeze them in place, preventing improvements and tweaks that can make all the difference in patient outcomes? The real question is: how do we balance price control with the need for medical progress?
- TCThe Cart Desk · editorial
The recent CMS proposal sends a clear signal: if your medicine doesn't sell well enough, it'll be lumped in with older treatments and priced accordingly. This stifles innovation, as investors are less likely to take risks on new medications if they won't reap the rewards for long. But what about existing medicines that are still effective? Why not grandfather them in under a separate tier, exempt from price controls? This would allow CMS to reap immediate cost savings while preserving incentives for future breakthroughs.
- PRPat R. · frugal living writer
The proposed CMS price controls may seem like a harmless tweak, but they could have a chilling effect on innovation in medicine. What's missing from this debate is the impact on small to mid-sized biotech firms that drive many of these breakthroughs. These companies often rely on venture capital funding to bring new treatments to market. By capping prices, CMS may inadvertently stifle the very engines of medical progress, forcing these firms to abandon promising research projects and leaving patients with fewer treatment options in the long run.